CLL / SLL Treatment and Research
Advancements are happening everyday
Treatment and research are intimately linked. The best treatments today may be upstaged by new therapies discovered in research in the future. Take your time to learn about treatment options currently available and new ones that are on the way.
Advancements are happening everyday
Treatment and research are intimately linked. The best treatments today may be upstaged by new therapies discovered in research in the future. Take your time and learn about what treatment options are now available and the new ones are on the way.
Treatment and Research: 4 Things to Know
CLL patients are living longer than ever.
The life expectancy of patients diagnosed with CLL / SLL has improved every decade, largely because of improved care made possible by new treatments and research.
CLL treatments are better than ever.
In almost every setting and in almost every subgroup studied, the newer targeted therapies approved since 2015 have proven superior to older protocols using chemotherapy.
Better single agents and drug combinations show promise.
New improved medications and drug combinations are constantly improving outcomes.
Research drives success.
CLL / SLL is not a solved problem and never will be without new treatments and more research.
CLL patients are living longer than ever.
The life expectancy of patients diagnosed with CLL / SLL has improved every decade, largely because of improved care made possible by new treatments and research.
CLL treatments are better than ever.
In almost every setting and in almost every subgroup studied, the newer targeted therapies approved since 2015 have proven superior to older protocols using chemotherapy.
Better single agents and drug combinations show promise.
New improved medications and drug combinations are constantly improving outcomes.
Research drives success.
CLL / SLL is not a solved problem and never will be without new treatments and more research.
FEATURE
BTK Degrader Offers Promise in Relapsed and Refractory CLL
The Bottom Line:
In heavily treated chronic lymphocytic leukemia patients who have poor prognoses and few options, the BTK degrader, NX-5948, saw 7 of the 10 treated respond.
Who Performed the Research and Where Was it Presented:
Dr. Kim Linton led an international group of researchers to present the oral abstract of these encouraging first results on the last day of the 2024 European Hematology Association (EHA) Annual Meeting in Madrid.
ADDITIONAL READING
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
